Dynavax Technologies (DVAX)
(Delayed Data from NSDQ)
$11.27 USD
+0.23 (2.08%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $11.05 -0.22 (-1.95%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Brokerage Reports
Dynavax Technologies Corporation [DVAX]
Reports for Purchase
Showing records 61 - 80 ( 124 total )
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Disappointing 2Q20 Heplisav-B Sales Due to COVID-19 Pandemic; Lowering PT by $2 to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Sale of SD-101 for Upfront Payments and Potential Milestone Payments; Raising PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Sixth Collaboration to Develop a COVID-19 Vaccine Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Collaboration With Mount Sinai to Develop a Universal Influenza Vaccine Candidate With CpG 1018 Adjuvant Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
First Participants Dosed in Phase 1 Trial Evaluating Medicago''s COVID-19 Vaccine Candidate With CpG 1018 Adjuvant
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Dynavax and Times Pharmacy Partnership With Hep Free Hawaii Offering Heplisav-B in Oahu Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
COVID-19 Vaccine Collaboration With Medicago Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Phase 1 Trial Evaluating COVID-19 Vaccine Utilizing the CpG 1018 Adjuvant
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
1Q20 Results: Sales Above Our Estimate as No Pandemic Impact Seen Until End of March; Study Timelines Unchanged
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Solid Interim Data from Trial Evaluating Heplisav- B in Hemodialysis Patients.
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
FY20 Heplisav-B Guidance Withdrawn Due to Pandemic
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Another Collaboration to Develop a COVID-19 Vaccine
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
4Q19 Results Below Expectations, but 2020 Sales Outlook Positive; Lowering PT by $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
3Q19 Results; Heplisav-B Sales Rise 22.4% Sequentially
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Dynavax Technologies Corporation
Industry: Medical - Biomedical and Genetics
Initiating With a Buy Rating and $13 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E